Workshop track 3 Workshop: Novel targets for controlling dyslipidaemias| Volume 287, e11, August 2019

Farnesoid X Receptor Activation Lowers Hdl-C But Increases Abca1-Specific Serum Hdl Cholesterol Efflux Capacity

      Background and Aims: The failure of drugs elevating HDL-C has put in question the role of HDL-C in atheroprotection. However, the ability of HDL to mediate cholesterol efflux has been associated with prevalence as well as incidence of cardiovascular disease independent of HDL-C. Stimulation of Farnesoid X receptor (FXR) by bile acids results in contradictory effects – while lowering plasma cholesterol (primarily HDL-C ∼-40%) it also increases reverse cholesterol transport and reduces atherosclerosis in mouse models. The aim of this study was to investigate the effect of FXR gain- and loss-of-function on HDL composition and function.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect